Cilostazol Impact on Cognitive and Motor Symptoms in Parkinson's Disease

This clinical trial is focused on evaluating the effects of the drug Cilostazol on patients with Parkinson's Disease. Parkinson's Disease is a progressive brain disorder that affects movement and can lead to cognitive decline. The disease is associated with the degeneration of dopamine-producing neurons and is influenced by factors like inflammation and oxidative stress. Cilostazol, which is already used to treat certain vascular conditions, has properties that could potentially protect brain cells by reducing inflammation and oxidative stress. This study is investigating whether Cilostazol can help slow down the progression of Parkinson's Disease and improve cognitive function in patients. Participants in the trial will receive Cilostazol, typically administered in pill form, to assess its impact on Parkinson's Disease symptoms and cognitive decline. The study will measure various outcomes, such as improvements in movement and cognitive abilities, to determine the drug's effectiveness. While Cilostazol has shown promise in preliminary studies, it is important to monitor for potential side effects, which can include headaches and gastrointestinal issues, among others. The goal of the study is to explore a novel treatment option that might offer better management of Parkinson's Disease symptoms and potentially slow its progression.